Filter posts

Watch-Out Tech Industry, Biotech is on the Rise in San Francisco

When thinking about the industries that make up San Francisco’s vibrant economy, biopharma is often …

Life Science Leader Asks: What Biopharma Trends Should Pharma Execs Be Paying Attention To?

In my last installment of this four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & …

State of the Industry for Emerging Therapeutic Companies

Emerging therapeutic companies are at their strongest point in a decade. In our new report …

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does …

The Good, the Bad, and the Ugly for Biotech IPOs

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They …

BIO Investor Forum: The New Kids on the Biotech Block

Where should biotech start-ups look for funding in the venture capital desert that is becoming …

How does the NBI perform in the last quarter of the year?

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months …

Does Biotech History Repeat?

According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …

Biopharma Industry Enthusiastic About 2012

By Eric S. Langer, president and managing partner, BioPlan Associates, Inc. 2012 Annual Study shows budgets, …